试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-01
A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee
编号:NCT00837291登记状态:入组前撤回企业 / 申办者:Can-Fite BioPharma
药物 / 成分:CF101、Placebo
登记的停止原因(原文):The company has decided not to conduct the study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-01
Safety &Efficacy of CF101 to Subjects With Uveitis
编号:NCT01905124登记状态:入组前撤回企业 / 申办者:Can-Fite BioPharma
药物 / 成分:CF101、Placebo
登记的停止原因(原文):The company has decided not to conduct the study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-01
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
编号:NCT01956864登记状态:入组前撤回企业 / 申办者:Johns Hopkins University
药物 / 成分:Vitamin D
登记的停止原因(原文):PI transferred from Georgetown to Johns Hopkins University. No participants enrolled at either site. Funding lapsed.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-31
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
编号:NCT00003534登记状态:入组前撤回企业 / 申办者:Burzynski Research Institute
药物 / 成分:Antineoplaston therapy (Atengenal + Astugenal)
登记的停止原因(原文):No participants enrolled.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-31
Studying the Efficacy of Aspirin & Clopidogrel in Healthy Subjects With Stable Coronary Artery Disease.
编号:NCT01011257登记状态:入组前撤回企业 / 申办者:Neil Kleiman, MD
药物 / 成分:Asprin、Clopidogrel
登记的停止原因(原文):No funding secured.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-31
Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes
编号:NCT02488616登记状态:入组前撤回企业 / 申办者:Institut de Recherches Cliniques de Montreal
药物 / 成分:5-day intervention with single-hormone closed-loop strategy、5-day intervention with sensor-augmented pump therapy、Insulin pump、Continuous glucose monitoring system
登记的停止原因(原文):Medtronic support terminated
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-31
Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery
编号:NCT02590497登记状态:入组前撤回企业 / 申办者:Ohio State University Comprehensive Cancer Center
药物 / 成分:Diffusion Weighted Imaging、Gadolinium、Laboratory Biomarker Analysis、Magnetic Resonance Imaging
登记的停止原因(原文):PI made decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-31
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
编号:NCT02815059登记状态:入组前撤回企业 / 申办者:University of Utah
药物 / 成分:Ibrutinib、Dasatinib、Prednisone
登记的停止原因(原文):Termination of Investigator Initiated Studies using Ibrutinib
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-31
Exploring the Impact of Perioperative Galacto-Oligosaccharides (GOS) on Stress, Anxiety and Cognition
编号:NCT02953691登记状态:入组前撤回企业 / 申办者:Jeff Taekman, M.D.
药物 / 成分:Galacto-Oligosaccharide、Maltodextrin (Placebo)
登记的停止原因(原文):Lack of Study Substance
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-01-30
A Comparison of Compliance Between Clonidine Patch and Methyldopa for the Treatment of Chronic Hypertension in Pregnancy
编号:NCT00329511登记状态:入组前撤回企业 / 申办者:Afshan B. Hameed, M.D.
药物 / 成分:methyldopa vs. clonidine、clonidine patch
登记的停止原因(原文):Feasibility of study. PI termination
查看官方原始记录 ↗